Diffuse Large B Cell Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab + polatuzumab vedotin-piiq Sensitive: A1 - Approval rituximab + polatuzumab vedotin-piiq Sensitive : A1	rituximab + polatuzumab vedotin-piiq Sensitive: A1 - Approval rituximab + polatuzumab vedotin-piiq Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	polatuzumab vedotin-piiq Sensitive: A1 - Approval polatuzumab vedotin-piiq Sensitive : A1	polatuzumab vedotin-piiq Sensitive: A1 - Approval polatuzumab vedotin-piiq Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: A1 - Approval loncastuximab tesirine-lpyl Sensitive : A1	loncastuximab tesirine-lpyl Sensitive: A1 - Approval loncastuximab tesirine-lpyl Sensitive : A1
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab + lenalidomide + brentuximab vedotin Sensitive: A1 - Approval rituximab + lenalidomide + brentuximab vedotin Sensitive : A1	rituximab + lenalidomide + brentuximab vedotin Sensitive: A1 - Approval rituximab + lenalidomide + brentuximab vedotin Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	selinexor Sensitive: A1 - Approval selinexor Sensitive : A1	selinexor Sensitive: A1 - Approval selinexor Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab/hyaluronidase Sensitive: A1 - Approval rituximab / hyaluronidase Sensitive : A1	rituximab/hyaluronidase Sensitive: A1 - Approval rituximab / hyaluronidase Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	glofitamab-gxbm Sensitive: A1 - Approval glofitamab-gxbm Sensitive : A1	glofitamab-gxbm Sensitive: A1 - Approval glofitamab-gxbm Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TNFRSF8 positive	Diffuse Large B Cell Lymphoma	TNFRSF8 positive	Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	carboplatin + gemcitabine + rituximab + dexamethasone Sensitive: A2 - Guideline carboplatin + gemcitabine + rituximab + dexamethasone Sensitive : A2	carboplatin + gemcitabine + rituximab + dexamethasone Sensitive: A2 - Guideline carboplatin + gemcitabine + rituximab + dexamethasone Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	carboplatin + gemcitabine + dexamethasone Sensitive: A2 - Guideline carboplatin + gemcitabine + dexamethasone Sensitive : A2	carboplatin + gemcitabine + dexamethasone Sensitive: A2 - Guideline carboplatin + gemcitabine + dexamethasone Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2

Diffuse Large B Cell Lymphoma

Associations(364)

Associations
(364)